Maxygen, Inc., a biopharmaceutical company, engages in developing various products in the field of human therapeutics in North America. It focuses on the development of MAXY-G34 product candidate, a granulocyte colony stimulating factor, for the treatment of chemotherapy-induced neutropenia and acute radiation syndrome. The company was founded in 1996 and is headquartered in San Mateo, California.